Collateral sensitivity as a strategy against cancer multidrug resistance

Akiyama, 1985, Isolation and genetic characterization of human KB cell lines resistant to multiple drugs, Somat. Cell Mol. Genet., 11, 117, 10.1007/BF01534700 al-Shawi, 1993, Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein, J. Biol. Chem., 268, 4197, 10.1016/S0021-9258(18)53597-3 Aleman, 2003, P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential, Cancer Res., 63, 3084 Ambudkar, 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu. Rev. Pharmacol. Toxicol., 39, 361, 10.1146/annurev.pharmtox.39.1.361 Barattin, 2010, Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1, Bioorg. Med. Chem., 18, 6265, 10.1016/j.bmc.2010.07.031 Bech-Hansen, 1976, Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity, J. Cell. Physiol., 88, 23, 10.1002/jcp.1040880104 Bell, 1998, 2-Deoxy-d-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis, Br. J. Cancer, 78, 1464, 10.1038/bjc.1998.708 Bentley, 1997, The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation, Cancer Lett., 115, 221, 10.1016/S0304-3835(97)04739-3 Berger, 2005, Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications, J. Cancer Res. Clin. Oncol., 131, 355, 10.1007/s00432-004-0653-9 Brough, 2011, Searching for synthetic lethality in cancer, Curr. Opin. Genet. Dev., 21, 34, 10.1016/j.gde.2010.10.009 Broxterman, 1988, Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells, FASEB J., 2, 2278, 10.1096/fasebj.2.7.3350243 Cairns, 2011, Regulation of cancer cell metabolism, Nat. Rev. Cancer, 11, 85, 10.1038/nrc2981 Calcagno, 2007, ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug–drug interactions, Curr. Drug Deliv., 4, 324, 10.2174/156720107782151241 Callaghan, 1995, Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane, Biochim. Biophys. Acta, 1236, 155, 10.1016/0005-2736(95)00042-2 Cano-Gauci, 1987, Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation, Biochem. Pharmacol., 36, 2115, 10.1016/0006-2952(87)90139-0 Cole, 2006, Transport of glutathione and glutathione conjugates by MRP1, Trends Pharmacol. Sci., 27, 438, 10.1016/j.tips.2006.06.008 Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 Fox, 2007, Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor, Expert Rev. Anticancer Ther., 7, 447, 10.1586/14737140.7.4.447 Ganguly, 2010, Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate, PLoS One, 5, e11253, 10.1371/journal.pone.0011253 Genoux-Bastide, 2011, Identification of Xanthones as Selective Killers of Cancer Cells Overexpressing the ABC Transporter MRP1, ChemMedChem, 6, 1478, 10.1002/cmdc.201100102 Goldsborough, 2011, Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin, J. Med. Chem., 54, 4987, 10.1021/jm2001663 Gottesman, 2009, Structure of a multidrug transporter, Nat. Biotechnol., 27, 546, 10.1038/nbt0609-546 Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer, 2, 48, 10.1038/nrc706 Hall, 2011, Synthesis and structure–activity evaluation of isatin-beta-thiosemicarbazones with improved selective activity towards multidrug-resistant cells expressing P-glycoprotein, J. Med. Chem., 54, 5878, 10.1021/jm2006047 Hall, 2009, Is resistance useless? Multidrug resistance and collateral sensitivity, Trends Pharmacol. Sci., 30, 546, 10.1016/j.tips.2009.07.003 Hall, 2009, Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells, J. Med. Chem., 52, 3191, 10.1021/jm800861c Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 He, 2003, Role of reduced glutathione efflux in apoptosis of immortalized human keratinocytes induced by UVA, J. Biol. Chem., 278, 8058, 10.1074/jbc.M207781200 Helson, 1984, Calcium channel blocker enhancement of anticancer drug cytotoxicity--a review, Cancer Drug Deliv., 1, 353, 10.1089/cdd.1984.1.353 Jansson, 2010, The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study, J. Inorg. Biochem., 104, 1224, 10.1016/j.jinorgbio.2010.07.012 Joly, 1999, Treatment of cystinuria, Pediatr. Nephrol., 13, 945, 10.1007/s004670050736 Kaplan, 1991, The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity, Cancer Res., 51, 1638 Kaplan, 1990, Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism, Cancer Res., 50, 544 Kappus, 1981, Toxic drug effects associated with oxygen metabolism: redox cycling and lipid peroxidation, Experientia, 37, 1233, 10.1007/BF01948335 Karwatsky, 2003, A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity, Biochemistry, 42, 12163, 10.1021/bi034149+ Keenan, 2004, Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants, Anticancer Res., 24, 433 Kelly, 2010, A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer, Clin. Cancer Res., 17, 569, 10.1158/1078-0432.CCR-10-1725 Koppenol, 2011, Otto Warburg's contributions to current concepts of cancer metabolism, Nat. Rev. Cancer, 11, 325, 10.1038/nrc3038 Kuo, 2011, A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways, Biochem. Pharmacol., 81, 1136, 10.1016/j.bcp.2011.02.013 Laberge, 2009, P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil, Arch. Biochem. Biophys., 491, 53, 10.1016/j.abb.2009.09.012 Le, 2004, Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation, Blood, 104, 2967, 10.1182/blood-2004-05-1866 Le, 2002, The role of iron in cell cycle progression and the proliferation of neoplastic cells, Biochim. Biophys. Acta, 1603, 31 Leonard, 2003, The role of ABC transporters in clinical practice, Oncologist, 8, 411, 10.1634/theoncologist.8-5-411 Loe, 2000, Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1), J. Pharmacol. Exp. Ther., 293, 530 Ludwig, 2006, Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer, Cancer Res., 66, 4808, 10.1158/0008-5472.CAN-05-3322 Lyon, 1988, Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy, Cancer Res., 48, 870 Marks, 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes, J. Nat. Prod., 74, 567, 10.1021/np100429s Muller, 1994, Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines, Int. J. Cancer, 56, 749, 10.1002/ijc.2910560523 Naito, 1989, Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement, Cancer Res., 49, 1452 Nakagawa-Goto, 2008, Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity, J. Med. Chem., 51, 3297, 10.1021/jm701208v Nakagawa-Goto, 2010, Antitumor agents 280. Multidrug resistance-selective desmosdumotin B analogues, J. Med. Chem., 53, 6699, 10.1021/jm100846r Nobili, 2011, Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression, Med. Res. Rev. Perrotton, 2007, (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1, J. Biol. Chem., 282, 31542, 10.1074/jbc.M703964200 Prisant, 2001, Verapamil revisited: a transition in novel drug delivery systems and outcomes, Heart Dis., 3, 55, 10.1097/00132580-200101000-00008 Robey, 2010, The challenge of exploiting ABCG2 in the clinic, Curr. Pharm. Biotechnol., 12, 595, 10.2174/138920111795163913 Robey, 2007, ABCG2: determining its relevance in clinical drug resistance, Cancer Metastasis Rev., 26, 39, 10.1007/s10555-007-9042-6 Szakacs, 2004, Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells, Cancer Cell, 6, 129, 10.1016/j.ccr.2004.06.026 Szakacs, 2006, Targeting multidrug resistance in cancer, Nat. Rev. Drug Discov., 5, 219, 10.1038/nrd1984 Szybalski, 1952, Genetic studies on microbial cross resistance to toxic agents: I. Cross resistance of Escherichia coli to fifteen antibiotics, J. Bacteriol., 64, 489, 10.1128/JB.64.4.489-499.1952 Tran, 2011, Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions, Nutr. Cancer, 63, 435, 10.1080/01635581.2011.535959 Trompier, 2004, Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1, Cancer Res., 64, 4950, 10.1158/0008-5472.CAN-04-0143 Tsuruo, 1983, Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers, Cancer Res., 43, 2905 Tsuruo, 1981, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res., 41, 1967 Turk, 2009, Identification of compounds selectively killing multidrug-resistant cancer cells, Cancer Res., 69, 8293, 10.1158/0008-5472.CAN-09-2422 Warr, 1988, Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells, Cancer Res., 48, 4477 Warr, 1986, Verapamil hypersensitivity of vincristine resistant Chinese hamster ovary cell lines, Cell Biol. Int. Rep., 10, 389, 10.1016/0309-1651(86)90011-1 Whitnall, 2006, A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics, Proc. Natl. Acad. Sci. U. S. A., 103, 14901, 10.1073/pnas.0604979103 Wu, 2007, Evidence for dual mode of action of a thiosemicarbazone. NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter, Mol. Cancer Ther., 6, 3287, 10.1158/1535-7163.MCT-07-2005 Xu, 2005, Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia, Cancer Res., 65, 613, 10.1158/0008-5472.613.65.2 Yuan, 2004, Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment, Blood, 104, 1450, 10.1182/blood-2004-03-0868 Zhou, 2008, Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition, Xenobiotica, 38, 802, 10.1080/00498250701867889